Single-molecule techniques to quantify and genetically characterise persistent HIV
Open Access
- 9 January 2018
- journal article
- review article
- Published by Springer Nature in Retrovirology
- Vol. 15 (1) , 3
Abstract
Antiretroviral therapy effectively suppresses, but does not eradicate HIV-1 infection. Persistent low-level HIV-1 can still be detected in plasma and cellular reservoirs even after years of effective therapy, and cessation of current treatments invariably results in resumption of viral replication. Efforts to eradicate persistent HIV-1 require a comprehensive examination of the quantity and genetic composition of HIV-1 within the plasma and infected cells located in the peripheral blood and tissues throughout the body. Single-molecule techniques, such as the single-copy assay and single-genome/proviral sequencing assays, have been employed to further our understanding of the source and viral dynamics of persistent HIV-1 during long-term effective therapy. The application of the single-copy assay, which quantifies plasma HIV-1 RNA down to a single copy, has revealed that viremia persists in the plasma and CSF after years of effective therapy. This low-level HIV-1 RNA also persists in the plasma following treatment intensification, treatment with latency reversing agents, cancer-related therapy, and bone marrow transplantation. Single-genome/proviral sequencing assays genetically characterise HIV-1 populations after passing through different selective pressures related to cell type, tissue type, compartment, or therapy. The application of these assays has revealed that the intracellular HIV-1 reservoir is stable and mainly located in CD4+ memory T cells. Moreover, this intracellular HIV-1 reservoir is primarily maintained by cellular proliferation due to homeostasis and antigenic stimulation, although cryptic replication may take place in anatomic sites where treatment is sub-optimal. The employment of single-genome/proviral sequencing showed that latency reversing agents broadly activate quiescent proviruses but do not clear the intracellular reservoir. Recently, full-length individual proviral sequencing assays have been developed and the application of these assays has revealed that the majority of intracellular HIV-1 DNA is genetically defective. In addition, the employment of these assays has shown that genetically intact proviruses are unequally distributed in memory T cell subsets during antiretroviral therapy. The application of single-molecule assays has enhanced the understanding of the source and dynamics of persistent HIV-1 in the plasma and cells of HIV-infected individuals. Future studies of the persistent HIV-1 reservoir and new treatment strategies to eradicate persistent virus will benefit from the utilization of these assays.Keywords
Funding Information
- NIH/NIAID: Delaney AIDS Research Enterprise (DARE) to Find a Cure (1U19AI096109, 1UM1AI126611-01)
- amfAR Research Consortium on HIV Eradication (ARCHE) Collaborative Research Grant from The Foundation for AIDS Research (amfAR 108074-50-RGRL)
- Australian Centre for HIV and Hepatitis Virology Research ((ACH2) 2015-43)
- Australian National Health and Medical Research Council (AAP1061681)
This publication has 83 references indexed in Scilit:
- A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral TherapyClinical Infectious Diseases, 2013
- HIV reservoirs and the possibility of a cure for HIV infectionJournal of Internal Medicine, 2011
- Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 + T Cell Model without Inducing Global T Cell ActivationJournal of Virology, 2011
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsNature Medicine, 2010
- Persistent Low‐Level Viremia in HIV‐1 Elite Controllers and Relationship to Immunologic ParametersThe Journal of Infectious Diseases, 2009
- HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferationNature Medicine, 2009
- Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five YearsJournal of Virology, 2003
- Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cellsNature Medicine, 2003
- HIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid TissuesImmunity, 2001
- Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapyProceedings of the National Academy of Sciences, 1997